Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial -

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial
Information type: Other primary research
Source: Journal of the American Medical Association
Specialities: Cardiovascular system disorders | Diabetes | Emergency medicine and urgent care | Renal and urologic disorders | Stroke
Summary
RCT of 6979 adults reported that linagliptin added to usual care vs placebo added to usual care resulted in a non-inferior risk of CV outcome (CV death, non-fatal MI or nonfatal stroke) over median 2.2 years (12.4% vs 12.1%; HR, 1.02; p<0.001 for non-inferiority).
UKMi comment
A secondary analysis of CARMELINA found that linagliptin did not affect the risk of hospitalisation for heart failure (HF) or other selected HF-related outcomes, including among participants with /without history of HF, across spectrum of kidney disease, and independent of previous left ventricular ejection fraction.
Related links: Secondary analysis